Adjuvant chemoradiation for gastric cancer with infusional 5-fluorouracil and cisplatin: A phase i study

Current Oncology

Volumn 17, Issue 4, 2010, Pages 34-41

  Kassam, Z ^a,b   Mackay, H ^a,b   Buckley, C A ^a   Fung, S ^a,b   Pintile, M ^a,b   Oza, A ^a   Brierley, J ^a,b   Swallow, C ^b,c   Cummings, B ^a,b   Knox, J J ^a   Kim, J ^a,b   Wong, R ^a,b   Siu, L ^a,b   Feld, R ^a,b   Ringash, J ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

5 fluorouracil; Adjuvant therapy; Chemoradiation; Cisplatin; Gastric cancer; Phase i study

Indexed keywords

CISPLATIN; FLUOROURACIL; ONDANSETRON; PROCHLORPERAZINE; RANITIDINE;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPHAGIA; FATIGUE; FEMALE; FOLLOW UP; GASTRITIS; GASTROINTESTINAL REFLUX; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEARTBURN; HUMAN; LETHARGY; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; RADIATION INDUCED EMESIS; SIDE EFFECT; SKIN TOXICITY; STOMACH ADENOCARCINOMA; STOMATITIS; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

EID: 78149424783     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v17i4.521     Document Type: Article

References (29)

1. Earle CC, Maroun J, Zuraw L, and members of the Gastrointestinal Cancer Disease Site Group Cancer Care Ontario Practice Guidelines Initiative. Neoadjuvant or Adjuvant Therapy for Resectable Gastric Cancer. Practice guideline report #2-14. Toronto, ON: Cancer Care Ontario, Program in Evidence-Based Care; 2003. [Available online at: www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=13970; cited June 8, 2010]
2. Macdonald JS, Smalley S, Benedetti J, et al. Postoperative combined radiation and chemotherapy improves disease-free survival (dfs) and overall survival (os) in resected adenocarcinoma of the stomach and gastroesophageal junction: update of the results of Intergroup Study INT-0116 (swog 9008) [abstract 6]. Proc Am Soc Clin Oncol Gastrointest Cancers Symp 2004;[Available online at www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view& confID=27&abstractID=538; cited June 8, 2010]
3. Kassam Z, Lockwood G, O'Brien C, et al. Conformal radiotherapy in the adjuvant treatment of gastric cancer: review of 82 cases. Int J Radiat Oncol Biol Phys 2006;65:713-19.
4. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-8.
5. Waters JS, Norman A, Cunningham D, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 1999;80:269-72.
6. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-7.
7. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage iib-iva carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999;17:1339-48.
8. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-53.
9. International Union Against Cancer. TNM Classification of Malignant Tumors. 6th ed. New York: Wiley Liss; 2002.
10. Ringash J, Perkins G, Brierley J, et al. imrt for adjuvant radiation in gastric cancer: a preferred plan? Int J Radiat Oncol Biol Phys 2005;63:732-8.
11. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30.
12. Radiation Therapy Oncology Group (rtog). rtog/eortc Late Radiation Morbidity Scoring Schema [Web page]. Philadelphia: rtog; n.d. [Available at: www.rtog.org/members/toxicity/late.html; cited June 20, 2010]
13. United States, National Institutes of Health, National Cancer Institute, Cancer Therapy Evaluation Program (ctep). Common Toxicity Criteria (CTC). Version 2. Bethesda, MD: ctep; 1999. [Available online at: ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv20_ 4-30-992.pdf; cited June 8, 2010]
14. United States, National Institutes of Health, National Cancer Institute (nci). Clinical Trials (pdq). Phase iii Randomized Study of Adjuvant Chemoradiation After Resection in Patients with Gastric or Gastroesophageal Adenocarcinoma [Web page]. Bethesda, MD: nci; 2002. [Available online at: www.cancer.gov/clinicaltrials/CALGB-80101; cited June 8, 2010]
15. Hughes BG, Yip D, Chao M, et al. Audit of postoperative chemoradiotherapy as adjuvant therapy for resected gastroesophageal adenocarcinoma: an Australian multicentre experience. ANZ J Surg 2004;74:951-6.
16. Park SH, Kim DY, Heo JS, et al. Postoperative chemoradiotherapy for gastric cancer. Ann Oncol 2003;14:1373-7.
17. Schwartz GK, Winter K, Minsky B, et al A randomized phase ii trial comparing two paclitaxel (p)-cisplatin (c) containing chemoradiation (crt) regimens as adjuvant therapy in resected gastric cancer (rtog Intergroup #0114) [abstract 4020]. Proc Am Soc Clin Oncol 2005:23;312s. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view. &confID=34&abstractID=30590; cited June 8, 2010]
18. Escudero MP, Alonso V, Valencia J, et al. Adjuvant postoperative chemoradiotherapy in gastric carcinoma [abstract 4168]. Proc Am Soc Clin Oncol 2004;22:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view& confID=26&abstractID=1634; cited June 8, 2010]
19. Sharma VB, Koong AC, Cho C, et al. Adjuvant chemoradiotherapy for T3, T4, or node positive gastric cancer: a phase ii trial [abstract 4139]. Proc Am Soc Clin Oncol 2004;22:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view& confID=26&abstractID=643; cited June 8, 2010]
20. Bokemeyer C. Adjuvant radiochemotherapy (rtx/ctx) using 5-fu/folinic acid (fa) /cisplatin (ddp) ± paclitaxel (p) and radiation in patients (pts) with completely (R0) resected high-risk gastric cancer (uicc stages ii-iv (M0)): an extended phase ii study of the aio/aro/aco [abstract 4036]. Proc Am Soc Clin Oncol 2004;22:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view& confID=26&abstractID=2875; cited June 8, 2010]
21. Leong T, Michael M, Foo K, et al. Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5- fluorouracil (ecf) and alternative regimens before and after chemoradiation. Br J Cancer 2003;89:1433-8.
22. Arcangeli G, Saracino B, Angelini F, Marchetti P, Tirindelli Danesi D. Postoperative adjuvant chemoradiation in completely resected locally advanced gastric cancer. Int J Radiat Oncol Biol Phys 2002;54:1069-75.
23. Buckley C, Ringash J, Brierley J, et al. Prospective phase 1 study of post-operative adjuvant radiochemotherapy for gastric cancer with infusional 5-fluorouracil and cisplatin: 2005 update [abstract 48]. Proc Am Soc Clin Oncol Gastrointest Cancers Symp 2005;[Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view& confID=36&abstractID=10286; cited June 8, 2010]
24. Wagner AD, Grothe W, Behl S, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2005;CD004064.
25. Al-Sarraf M, Martz K, Herskovic A, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an Intergroup study. J Clin Oncol 1997;15:277-84.
26. Al-Sarraf M, Pajak TF, Byhardt RW, Beitler JJ, Salter MM, Cooper JS. Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, resectable head and neck cancers: rtog 88-24. Int J Radiat Oncol Biol Phys 1997;37:777-82.
27. Kollmannsberger C, Budach W, Stahl M, et al. Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase ii studies of the aio/aro/aco. Ann Oncol 2005;16:1326-33.
28. Lee HS, Choi Y, Hur WJ, et al. Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-fu/cisplatin and chemoradiation with capecitabine. World J Gastroenterol 2006;12:603-7.
29. Jansen EP, Boot H, Dubbelman R, Bartelink H, Cats A, Verheij M. Postoperative chemoradiotherapy in gastric cancer-a phase i/ii dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy. Br J Cancer 2007;97:712-16.